Published in Breast Cancer Res on December 08, 2011
RNA-Seq of human breast ductal carcinoma in situ models reveals aldehyde dehydrogenase isoform 5A1 as a novel potential target. PLoS One (2012) 0.84
Advances in the proteomic discovery of novel therapeutic targets in cancer. Drug Des Devel Ther (2013) 0.82
In vivo capture and label-free detection of early metastatic cells. Nat Commun (2015) 0.81
Using passenger mutations to estimate the timing of driver mutations and identify mutator alterations. BMC Bioinformatics (2013) 0.78
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
The sequence of the human genome. Science (2001) 101.55
Molecular portraits of human breast tumours. Nature (2000) 94.14
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
International network of cancer genome projects. Nature (2010) 20.35
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 16.25
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med (2007) 13.39
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res (2009) 9.59
Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol (2004) 9.38
Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer (2004) 9.24
Gene-expression signatures in breast cancer. N Engl J Med (2009) 9.23
Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med (2010) 8.71
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol (2007) 8.65
Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ (2009) 8.31
Molecular basis of metastasis. N Engl J Med (2008) 8.19
Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer (2008) 7.99
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med (2008) 7.37
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol (2006) 7.24
A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet (2006) 7.16
The case for early detection. Nat Rev Cancer (2003) 6.96
Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet (1987) 6.91
A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86
Genetic determinants of cancer metastasis. Nat Rev Genet (2007) 6.38
BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer (2004) 6.24
Metastatic behavior of breast cancer subtypes. J Clin Oncol (2010) 6.17
Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med (2006) 6.04
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA (2011) 4.63
American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol (2006) 4.61
Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res (2004) 4.48
Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am (1992) 4.34
Cancer micrometastases. Nat Rev Clin Oncol (2009) 3.69
Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics (2009) 3.65
Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci Transl Med (2010) 3.43
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics (2008) 3.24
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol (2010) 2.91
Nanoplatforms for targeted molecular imaging in living subjects. Small (2007) 2.69
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol (2010) 2.60
Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol (2006) 2.48
The effect of mass screening in Iceland, 1965-74, on the incidence and mortality of cervical carcinoma. Int J Cancer (1978) 2.34
A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res (2008) 2.16
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat (2010) 2.12
Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol (2009) 1.93
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat (2009) 1.84
Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res (2010) 1.81
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat (2010) 1.75
Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res (2008) 1.59
Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin Cancer Res (2003) 1.53
Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol (2010) 1.47
The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol (2009) 1.44
Effect of organized screening on the risk of cervical cancer. Evaluation of screening activity in Iceland, 1964-1991. Int J Cancer (1993) 1.43
Metastasis: new perspectives on an old problem. Mol Cancer (2011) 1.42
The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Int J Cancer (2009) 1.34
Mechanisms of metastasis. Breast Cancer Res (2008) 1.34
Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J Nucl Med (2009) 1.33
Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res (2009) 1.28
Specificity of choline metabolites for in vivo diagnosis of breast cancer using 1H MRS at 1.5 T. Eur Radiol (2004) 1.21
Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry. Mol Cell Proteomics (2009) 1.21
New technologies for the detection of circulating tumour cells. Br Med Bull (2010) 1.20
Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. Eur J Cancer (2010) 1.12
Current affairs in quantitative targeted proteomics: multiple reaction monitoring-mass spectrometry. Brief Funct Genomic Proteomic (2009) 1.09
The evolving role of mass spectrometry in cancer biomarker discovery. Cancer Biol Ther (2009) 1.09
Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol (2009) 1.07
The influence of basal phenotype on the metastatic pattern of breast cancer. Clin Oncol (R Coll Radiol) (2007) 1.03
FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis. J Cancer Res Clin Oncol (2010) 0.95
Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol (2010) 0.86
Fast dixon-based multisequence and multiplanar MRI for whole-body detection of cancer metastases. J Magn Reson Imaging (2009) 0.86
Tumor cell detection in peripheral blood and bone marrow. Curr Opin Oncol (2006) 0.85
Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther (2010) 0.85
Application of breast MRI for prediction of lymph node metastases - systematic approach using 17 individual descriptors and a dedicated decision tree. Acta Radiol (2010) 0.81
Molecular imaging of the breast. AJR Am J Roentgenol (2009) 0.76
Metastatic gene signatures and emerging novel prognostic tests in the management of early stage breast cancer. Clin Exp Metastasis (2009) 0.76
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05
Induction of tumors in mice by genomic hypomethylation. Science (2003) 8.86
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A (2004) 7.96
End-sequence profiling: sequence-based analysis of aberrant genomes. Proc Natl Acad Sci U S A (2003) 7.70
Chromosome aberrations in solid tumors. Nat Genet (2003) 7.01
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol (2007) 5.81
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet (2005) 4.70
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med (2004) 4.69
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
Translating insights from the cancer genome into clinical practice. Nature (2008) 4.37
In situ analyses of genome instability in breast cancer. Nat Genet (2004) 4.32
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med (2011) 4.10
Restriction of receptor movement alters cellular response: physical force sensing by EphA2. Science (2010) 3.72
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res (2010) 3.53
Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer (2006) 3.34
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics (2010) 3.25
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14
Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A (2011) 3.10
Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A (2005) 2.96
Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res (2007) 2.94
Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res (2006) 2.86
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol (2012) 2.85
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat (2011) 2.73
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther (2006) 2.55
Modeling precision treatment of breast cancer. Genome Biol (2013) 2.42
Temporal dissection of tumorigenesis in primary cancers. Cancer Discov (2011) 2.40
Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res (2006) 2.37
HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat (2009) 2.34
A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell (2005) 2.27
Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro Oncol (2009) 2.23
Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res (2011) 2.12
Decoding the fine-scale structure of a breast cancer genome and transcriptome. Genome Res (2006) 2.09
Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma. Cancer Res (2004) 1.98
Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res (2002) 1.96
A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov (2012) 1.87
Exon-level microarray analyses identify alternative splicing programs in breast cancer. Mol Cancer Res (2010) 1.84
A human breast cell model of preinvasive to invasive transition. Cancer Res (2008) 1.79
Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res (2007) 1.79
Analysis of molecular inversion probe performance for allele copy number determination. Genome Biol (2007) 1.78
Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat Chem Biol (2013) 1.75
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell (2013) 1.73
Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet (2002) 1.70
Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res (2003) 1.67
Cellular effect of high doses of silica-coated quantum dot profiled with high throughput gene expression analysis and high content cellomics measurements. Nano Lett (2006) 1.63
Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice. Cancer Cell (2007) 1.59
Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer (2007) 1.57
Invariant delineation of nuclear architecture in glioblastoma multiforme for clinical and molecular association. IEEE Trans Med Imaging (2012) 1.53
Molecular characterization of the cytotoxic mechanism of multiwall carbon nanotubes and nano-onions on human skin fibroblast. Nano Lett (2005) 1.53
Rbfox proteins regulate alternative mRNA splicing through evolutionarily conserved RNA bridges. Nat Struct Mol Biol (2013) 1.49
CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res (2013) 1.48
Molecular predictors of 3D morphogenesis by breast cancer cell lines in 3D culture. PLoS Comput Biol (2010) 1.46
A sequence-based survey of the complex structural organization of tumor genomes. Genome Biol (2008) 1.45
A nanoplasmonic molecular ruler for measuring nuclease activity and DNA footprinting. Nat Nanotechnol (2006) 1.44
Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res (2009) 1.43
Picomolar sensitivity MRI and photoacoustic imaging of cobalt nanoparticles. Proc Natl Acad Sci U S A (2009) 1.43
EGFR Intron 1 polymorphism in Asian Populations and its correlation with EGFR gene expression and amplification in breast tumor tissues. Cancer Biol Ther (2006) 1.42
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther (2006) 1.41
Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res (2007) 1.34
A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancer. Proc Natl Acad Sci U S A (2004) 1.33
ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet (2008) 1.33
Genome amplification of chromosome 20 in breast cancer. Breast Cancer Res Treat (2003) 1.29
High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays. BMC Med Genomics (2009) 1.29
The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer. Breast Cancer Res (2010) 1.29
Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc Natl Acad Sci U S A (2013) 1.27
Morphometic analysis of TCGA glioblastoma multiforme. BMC Bioinformatics (2011) 1.26
Integrated analysis of breast cancer cell lines reveals unique signaling pathways. Genome Biol (2009) 1.25
COMPARISON OF SPARSE CODING AND KERNEL METHODS FOR HISTOPATHOLOGICAL CLASSIFICATION OF GLIOBASTOMA MULTIFORME. Proc IEEE Int Symp Biomed Imaging (2011) 1.24
A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. BMC Med (2009) 1.22
Copy number aberrations in mouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling. Cancer Res (2005) 1.20
Biallelic inactivation of the thyroid hormone receptor beta1 gene in early stage breast cancer. Cancer Res (2002) 1.19
Identification of PADI2 as a potential breast cancer biomarker and therapeutic target. BMC Cancer (2012) 1.18
Bayesian inference of signaling network topology in a cancer cell line. Bioinformatics (2012) 1.17
Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. Breast Cancer Res (2007) 1.15
What are we learning from the cancer genome? Nat Rev Clin Oncol (2012) 1.13
Quantum dots-based reverse phase protein microarray. Talanta (2005) 1.12
Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression. Int J Cancer (2007) 1.10
c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells. Cancer Res (2013) 1.09
Array comparative genomic hybridization with cyanin cis-platinum-labeled DNAs. Biotechniques (2004) 1.09
High-throughput method for analyzing methylation of CpGs in targeted genomic regions. Proc Natl Acad Sci U S A (2010) 1.08
Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERα-positive breast cancer. Mol Cancer Res (2011) 1.08
Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer. Clin Cancer Res (2010) 1.06
Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev (2006) 1.06
The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov (2012) 1.06
Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis. Mol Oncol (2008) 1.04
Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress. EMBO Mol Med (2012) 1.03
A fluid membrane-based soluble ligand-display system for live-cell assays. Chembiochem (2006) 1.03
Qdot nanobarcodes for multiplexed gene expression analysis. Nano Lett (2006) 1.02
Lectin chromatography/mass spectrometry discovery workflow identifies putative biomarkers of aggressive breast cancers. J Proteome Res (2012) 1.01
Genetic differences in transcript responses to low-dose ionizing radiation identify tissue functions associated with breast cancer susceptibility. PLoS One (2012) 1.00
A primer on regression methods for decoding cis-regulatory logic. PLoS Comput Biol (2009) 1.00
The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. Cancer Res (2004) 0.98
Loss of cell-surface laminin anchoring promotes tumor growth and is associated with poor clinical outcomes. Cancer Res (2012) 0.98